Abstract: Some embodiments include an integrated assembly having a carrier-sink-structure, and having digit lines over the carrier-sink-structure. Transistor body regions are over the digit lines. Extensions extend from the carrier-sink-structure to the transistor body regions. The extensions are configured to drain excess carriers from the transistor body regions. Lower source/drain regions are between the transistor body regions and the digit lines, and are coupled with the digit lines. Upper source/drain regions are over the transistor body regions, and are coupled with storage elements. Gates are adjacent the transistor body regions. The transistor body regions, lower source/drain regions and upper source/drain regions are together comprised a plurality of transistors. The transistors and the storage elements are together comprised by a plurality of memory cells of a memory array. Some embodiments include methods of forming integrated assemblies.

Abstract: The disclosure relates to a method of coding implemented by a decoding device, comprising: obtaining a value of a maximum number of merging motion vector prediction, MVP, candidates for a current block, wherein the current block is predicted using intra block copy, IBC mode; setting a value of a MVP index to zero, when the value of the maximum number of MVP candidates for the current block is equal to one; obtaining a motion vector of the current block according to the MVP index and a candidate list; obtaining prediction samples values of the current block according to the motion vector of the current block.

Abstract: A method for selecting a grasp posture of a dual-arm robot includes: setting a fitness value range, an iteration quantity threshold, and a fitness function; calculating the fitness value of the population, determining whether the population is within the value range, ending an iteration if the population is within the value range or continuing to determine whether a quantity of iterations reaches the iteration quantity threshold if the population is not within the value range, ending the iteration if the quantity of iterations reaches the iteration quantity threshold or performing crossover and mutation operations if the quantity of iterations does not reach the iteration quantity threshold, and dynamically selecting a gene retention strategy based on an iteration depth and a fitness value to retain a gene; updating a gene population representing a grasping position and performing determining cyclically; and obtaining an optimal target corresponding to dual arms after the iteration.

Abstract: A pharmaceutical composition and a method for treating knee and/or hip pain in a patient non-responsive or intolerant to standard analgesic therapy are disclosed. A pharmaceutical composition and a method for reducing risk for developing an arthropathy in a subject receiving an anti-NGF antibody for treatment of knee and/or hip pain are disclosed. Also provided herein are methods for monitoring safety of a treatment of knee and/or hip pain involving administration of an anti-NGF antibody. In certain aspects, the subject has osteoarthritis of the knee and/or hip and the anti-NGF antibody is fasinumab.

Abstract: The disclosure relates to system and method for image quality detection. The method may include: obtaining an image acquired by a camera; obtaining an image quality detection model, the image quality detection model being provided by training a machine learning model using a plurality of training samples; determining a detection result of the image using the image quality detection model; and in response to a determination that the detection result includes a quality anomaly of the image, generating a strategy in response to the quality anomaly.

Abstract: A pharmaceutical composition and a method for treating knee and/or hip pain in a patient non-responsive or intolerant to standard analgesic therapy are disclosed. A pharmaceutical composition and a method for reducing risk for developing an arthropathy in a subject receiving an anti-NGF antibody for treatment of knee and/or hip pain are disclosed. Also provided herein are methods for monitoring safety of a treatment of knee and/or hip pain involving administration of an anti-NGF antibody. In certain aspects, the subject has osteoarthritis of the knee and/or hip and the anti-NGF antibody is fasinumab.